Tychon Bioscience is pioneering a novel approach to cancer treatment through its innovative oncolytic immunotherapy, specifically utilizing a technology called PAR-T cells. This method involves reprogramming a patient’s immune cells to become PAR-T cells, which are designed to identify and destroy cancer cells effectively. The therapy addresses common limitations associated with traditional T-cell based immunotherapies, such as slow clinical adoption and efficacy in solid tumors. Tychon’s PAR-T technology can be employed as a standalone treatment or in conjunction with other therapies, thereby enhancing its potential to treat various stages of cancer, including both early and late-stage forms.

The company’s lead product, TYC201, is a protein-based drug that activates T-cells to target and eliminate cancer cells, offering several advantages over existing therapies. These include minimal cytokine activation, rapid availability as an off-the-shelf therapy, cost-effective protein manufacturing, and a patient-friendly weekly dosing regimen. Additionally, the therapy can be controlled and even "turned off" using a common antibiotic, providing a level of safety and flexibility in treatment. Tychon’s focus on solid tumors has yielded promising preclinical results, particularly against breast, lung, prostate, and ovarian cancers, showcasing the potential of their PAR-T technology in advancing cancer immunotherapy.

United States

Tychon Biosciences is a biotechnology company commercializing novel technology in the rapidly expanding Immuno-oncology marketplace that offers similar high-specificity cancer killing relative to recently-approved cancer therapies, yet with increased safety and decreased cost.  Using Tychon’s BiND platform, a first-in-class bi-specific nanoring platform as an immediate therapy that targets both an antigen receptor on a cancer cell, and T-cell—binding them together and allowing your T-cells to attack cancer cells naturally without the need for genetic engineering.

Tychon Bioscience

Company Details